Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Osteoarthritis directly linked to low-fat, high-carb food

Osteoarthritis is a degenerative joint disease and the most common cause of disability today. It was once considered a problem of the old but it is now commonly diagnosed in those as young as the mid-twenties and early thirties. According to the Arthritis Foundation, about four million, quality-adjusted life years are lost due to knee osteoarthritis alone.

20 May 2011

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

Omeros advances OMS103HP and OMS302 into Phase 3 clinical programs

Omeros Corporation today announced that it is advancing two of its product candidates from its PharmacoSurgery platform – OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery – into Phase 3 clinical development programs.

19 May 2011

TissueGene commences enrollment in TG-C Phase II trial for severe knee osteoarthritis

TissueGene, Inc. announced today that it has initiated patient enrollment for a U.S. Phase II clinical trial of its lead product candidate TG-C. TG-C involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 for the regeneration of cartilage in patients suffering from severe osteoarthritis of the knee.

19 May 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011

Histogenics announces acquisition of ProChon Biotech

Histogenics Corporation, a privately held regenerative medicine company, announced today that it has acquired ProChon Biotech, Ltd. in a stock-for-stock exchange.

17 May 2011

Nuvo Research acquires ZARS Pharma

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has completed its acquisition of ZARS Pharma, Inc.

13 May 2011

Second subject enrolled in human embryonic stem cell therapy trial for subacute thoracic spinal cord injury

Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury.

11 May 2011

Geron comments on recent European telomerase peptide cancer vaccine patents

Geron Corporation today commented on a ruling from the European Patent Office with regard to its European patent 084139, and the issuance of a second Geron patent covering telomerase peptides, EP1783139.

10 May 2011

Unigene first quarter net loss decreases 58% to $6.6 million

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced first quarter financial results for the period ended March 31, 2011. The Company highlighted significant progress achieved in the first quarter with the execution of its turnaround strategy.

9 May 2011

U.S. Physical Therapy first quarter net revenue increases 12.6% to $56,741,000

U.S. Physical Therapy, Inc., a national operator of outpatient physical therapy clinics, today reported results for the first quarter ended March 31, 2011.

6 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

Artimplant reports net revenue of SEK 5.4 million for January - March, 2011

Artimplant AB: January 1 - March 31, 2011: Net revenue amounted to SEK 5.4 million.

4 May 2011

Legislative approaches needed to address obesity epidemic in Canada

With the increase in numbers of overweight children and young adults, Canada and other developed countries are facing an obesity epidemic and legislative approaches are required to address this issue, states an article in CMAJ (Canadian Medical Association Journal).

28 Apr 2011

Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausal women

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

28 Apr 2011

Advanced Orthopaedics & Spine Medicine to participate in iUni G2 knee implant trial

Dr. David Mack of Advanced Orthopaedics & Spine Medicine and North Cypress Medical Center are participating in a ten year follow-up trial of the ConforMIS iUni® G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

Performance Orthopedics to participate in iUni G2 knee implant trial

Dr. Gregory Martin of Performance Orthopedics of the Palm Beaches is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

Brookside Surgery Center to participate in iUni G2 knee implant trial

Dr. Joseph Burkhardt of Brookside Surgery Center is participating in a ten year follow-up trial of the ConforMIS iUni G2 knee resurfacing device, an FDA cleared implant for patients with osteoarthritic damage in a single compartment of the knee.

27 Apr 2011

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it and AstraZeneca filed a lawsuit against Dr. Reddy's Laboratories (Dr. Reddy's) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets.

25 Apr 2011